Skip to Content

475 (Imatinib mesylate 400 mg)

Pill imprint 475 has been identified as Imatinib mesylate 400 mg.

Imatinib is used in the treatment of chronic myelogenous leukemia; gastrointestinal stromal tumor; acute lymphoblastic leukemia; dermatofibrosarcoma protuberans; chronic eosinophilic leukemia (and more), and belongs to the drug class BCR-ABL tyrosine kinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Imatinib 400 mg is not a controlled substance under the Controlled Substance Act (CSA).

Imatinib mesylate 400 mg 475
Imatinib mesylate 400 mg 475
Discount Card Promo
Imatinib mesylate
400 mg
Elliptical / Oval
Prescription only
Drug Class:
BCR-ABL tyrosine kinase inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Sun Pharma Global FZE

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.